These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22093514)

  • 1. The year in non-ST-segment elevation acute coronary syndrome.
    Giugliano RP; Braunwald E
    J Am Coll Cardiol; 2011 Nov; 58(22):2342-54. PubMed ID: 22093514
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
    Fuster V; Sweeny JM
    JAMA; 2010 Oct; 304(16):1839-40. PubMed ID: 20978263
    [No Abstract]   [Full Text] [Related]  

  • 3. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
    Cuisset T; Quilici J; Cohen W; Fourcade L; Saut N; Pankert M; Gaborit B; Carrieri P; Morange PE; Bonnet JL; Alessi MC
    Am J Cardiol; 2011 Sep; 108(6):760-5. PubMed ID: 21803320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy.
    Pride YB; Tung P; Mohanavelu S; Zorkun C; Wiviott SD; Antman EM; Giugliano R; Braunwald E; Gibson CM;
    JACC Cardiovasc Interv; 2010 Aug; 3(8):806-11. PubMed ID: 20723851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome p-450 polymorphisms and response to clopidogrel.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
    N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 7. Another step on the road to tailored antiplatelet therapy.
    Wiviott SD; Mega JL
    J Am Coll Cardiol; 2010 Nov; 56(20):1637-8. PubMed ID: 21050972
    [No Abstract]   [Full Text] [Related]  

  • 8. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R; Pocock SJ; Nikolsky E; Clayton T; Dangas GD; Kirtane AJ; Parise H; Fahy M; Manoukian SV; Feit F; Ohman ME; Witzenbichler B; Guagliumi G; Lansky AJ; Stone GW
    J Am Coll Cardiol; 2010 Jun; 55(23):2556-66. PubMed ID: 20513595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to antiplatelet treatment: from genes to outcome.
    Giusti B; Abbate R
    Lancet; 2010 Oct; 376(9749):1278-81. PubMed ID: 20801497
    [No Abstract]   [Full Text] [Related]  

  • 11. Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies.
    Lefebvre CW; Hoekstra J
    Hosp Pract (1995); 2010 Apr; 38(2):40-9. PubMed ID: 20469612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
    Hamm CW; Bassand JP; Agewall S; Bax J; Boersma E; Bueno H; Caso P; Dudek D; Gielen S; Huber K; Ohman M; Petrie MC; Sonntag F; Uva MS; Storey RF; Wijns W; Zahger D;
    Eur Heart J; 2011 Dec; 32(23):2999-3054. PubMed ID: 21873419
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
    Tello-Montoliu A; Jover E; Marín F; Bernal A; Lozano ML; Sánchez-Vega B; Pastor FJ; Hurtado JA; Valdés M; Vicente V; Rivera J
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):219-26. PubMed ID: 22116003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
    Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
    Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modern treatment in acute coronary syndrome].
    Bauer T; Zahn R
    Dtsch Med Wochenschr; 2012 Apr; 137(14):722-5. PubMed ID: 22454203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?".
    Croce K
    Circ Cardiovasc Interv; 2010 Feb; 3(1):3-5. PubMed ID: 20160184
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?
    Saucedo JF
    Am J Cardiol; 2009 Sep; 104(5 Suppl):4C-8C. PubMed ID: 19695354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
    Bonello L; Armero S; Ait Mokhtar O; Mancini J; Aldebert P; Saut N; Bonello N; Barragan P; Arques S; Giacomoni MP; Bonello-Burignat C; Bartholomei MN; Dignat-George F; Camoin-Jau L; Paganelli F
    J Am Coll Cardiol; 2010 Nov; 56(20):1630-6. PubMed ID: 20708365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
    Angiolillo DJ; Ueno M
    JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.